US 12,075,980 B2
Systems and methods for visualizing ablated tissue
Omar Amirana, Cambridge, MA (US); Kenneth C. Armstrong, Cary, NC (US); Matthew W. Kay, Kensington, MD (US); Marco A. Mercader, Arlington, VA (US); Terrance J. Ransbury, Chapel Hill, NC (US); and Narine Sarvazyan, Potomac, MD (US)
Assigned to The George Washington University, Washington, DC (US); and 460Medical, Inc., Weston, MA (US)
Filed by The George Washington University, Washington, DC (US); and 460Medical, Inc., Weston, MA (US)
Filed on Jan. 20, 2023, as Appl. No. 18/099,480.
Application 18/099,480 is a continuation of application No. 16/879,929, filed on May 21, 2020, granted, now 11,559,192, issued on Jan. 24, 2023.
Application 16/879,929 is a continuation of application No. 15/986,970, filed on May 23, 2018, granted, now 10,716,462, issued on Jul. 21, 2020.
Application 15/986,970 is a continuation of application No. 14/689,475, filed on Apr. 17, 2015, granted, now 10,076,238, issued on Sep. 18, 2018.
Application 14/689,475 is a continuation in part of application No. 13/624,899, filed on Sep. 22, 2012, granted, now 9,014,789, issued on Apr. 21, 2015.
Application 13/624,899 is a continuation of application No. 13/624,902, filed on Sep. 22, 2012, granted, now 9,084,611, issued on Jul. 21, 2015.
Claims priority of provisional application 61/537,798, filed on Sep. 22, 2011.
Prior Publication US 2023/0293000 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 1/04 (2006.01); A61B 1/00 (2006.01); A61B 1/05 (2006.01); A61B 1/06 (2006.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); A61B 5/1459 (2006.01); A61B 18/00 (2006.01); A61B 18/14 (2006.01); A61B 90/00 (2016.01); A61B 90/30 (2016.01); A61B 90/35 (2016.01); A61B 18/02 (2006.01); A61B 34/30 (2016.01)
CPC A61B 1/043 (2013.01) [A61B 1/00009 (2013.01); A61B 1/00045 (2013.01); A61B 1/00082 (2013.01); A61B 1/00186 (2013.01); A61B 1/05 (2013.01); A61B 1/0638 (2013.01); A61B 1/0676 (2013.01); A61B 1/0684 (2013.01); A61B 5/004 (2013.01); A61B 5/0044 (2013.01); A61B 5/0084 (2013.01); A61B 5/14503 (2013.01); A61B 5/14546 (2013.01); A61B 5/1459 (2013.01); A61B 5/6853 (2013.01); A61B 18/00 (2013.01); A61B 18/1492 (2013.01); A61B 90/30 (2016.02); A61B 90/35 (2016.02); A61B 90/361 (2016.02); A61B 2018/0022 (2013.01); A61B 2018/0212 (2013.01); A61B 2034/301 (2016.02); A61B 2090/365 (2016.02); Y02A 90/10 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A system for imaging tissue, the system being configured for use in connection with tissue ablation, comprising:
a light source providing light for illuminating a tissue to excite mitochondrial nicotinamide adenine dinucleotide hydrogen (NADH) in the tissue;
a sensor for detecting NADH fluorescence from the illuminated tissue; and
a processor programmed to perform the steps of:
obtaining the detected NADH fluorescence from the sensor during ablation of the tissue,
generating a digital representation of the detected NADH fluorescence for monitoring a progression of the ablation of the tissue, and
while the tissue is being ablated, determining a decrease in the detected NADH fluorescence and updating the digital representation to show the measured decrease in the detected NADH fluorescence that is indicative of the progression of the ablation of the tissue.